Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04190550
Title Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Cytarabine + Idarubicin + KRT-232

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Los Angeles County-USC Medical Center Recruiting Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Recruiting Los Angeles California 90033 United States Details
Northwestern University Active, not recruiting Chicago Illinois 60611 United States Details
University of Maryland/Greenebaum Cancer Center Recruiting Baltimore Maryland 21201 United States Details
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting New York New York 10016 United States Details
University of Oklahoma Health Sciences Center Recruiting Oklahoma City Oklahoma 73104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field